823 related articles for article (PubMed ID: 29342248)
1. Clinical considerations of the role of palbociclib in the management of advanced breast cancer patients with and without visceral metastases.
Turner NC; Finn RS; Martin M; Im SA; DeMichele A; Ettl J; Diéras V; Moulder S; Lipatov O; Colleoni M; Cristofanilli M; Lu DR; Mori A; Giorgetti C; Iyer S; Bartlett CH; Gelmon KA
Ann Oncol; 2018 Mar; 29(3):669-680. PubMed ID: 29342248
[TBL] [Abstract][Full Text] [Related]
2. Palbociclib plus endocrine therapy in older women with HR+/HER2- advanced breast cancer: a pooled analysis of randomised PALOMA clinical studies.
Rugo HS; Turner NC; Finn RS; Joy AA; Verma S; Harbeck N; Masuda N; Im SA; Huang X; Kim S; Sun W; Iyer S; Schnell P; Bartlett CH; Johnston S
Eur J Cancer; 2018 Sep; 101():123-133. PubMed ID: 30053671
[TBL] [Abstract][Full Text] [Related]
3. Analysis of subsequent therapy in Japanese patients with hormone receptor‒positive/human epidermal growth factor receptor 2‒negative advanced breast cancer who received palbociclib plus endocrine therapy in PALOMA-2 and -3.
Masuda N; Mukai H; Inoue K; Rai Y; Ohno S; Ohtani S; Shimizu C; Hashigaki S; Muramatsu Y; Umeyama Y; Iwata H; Toi M
Breast Cancer; 2021 Mar; 28(2):335-345. PubMed ID: 33085032
[TBL] [Abstract][Full Text] [Related]
4. Palbociclib Combined with Fulvestrant in Premenopausal Women with Advanced Breast Cancer and Prior Progression on Endocrine Therapy: PALOMA-3 Results.
Loibl S; Turner NC; Ro J; Cristofanilli M; Iwata H; Im SA; Masuda N; Loi S; André F; Harbeck N; Verma S; Folkerd E; Puyana Theall K; Hoffman J; Zhang K; Bartlett CH; Dowsett M
Oncologist; 2017 Sep; 22(9):1028-1038. PubMed ID: 28652278
[TBL] [Abstract][Full Text] [Related]
5. Predictors of prolonged benefit from palbociclib plus fulvestrant in women with endocrine-resistant hormone receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer in PALOMA-3.
Cristofanilli M; DeMichele A; Giorgetti C; Turner NC; Slamon DJ; Im SA; Masuda N; Verma S; Loi S; Colleoni M; Theall KP; Huang X; Liu Y; Bartlett CH
Eur J Cancer; 2018 Nov; 104():21-31. PubMed ID: 30308388
[TBL] [Abstract][Full Text] [Related]
6. Progression-free Survival Outcome Is Independent of Objective Response in Patients With Estrogen Receptor-positive, Human Epidermal Growth Factor Receptor 2-negative Advanced Breast Cancer Treated With Palbociclib Plus Letrozole Compared With Letrozole: Analysis From PALOMA-2.
Rugo HS; Finn RS; Gelmon K; Joy AA; Harbeck N; Castrellon A; Mukai H; Walshe JM; Mori A; Gauthier E; Lu DR; Bananis E; Martin M; Diéras V
Clin Breast Cancer; 2020 Apr; 20(2):e173-e180. PubMed ID: 31836434
[TBL] [Abstract][Full Text] [Related]
7. Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial.
Cristofanilli M; Turner NC; Bondarenko I; Ro J; Im SA; Masuda N; Colleoni M; DeMichele A; Loi S; Verma S; Iwata H; Harbeck N; Zhang K; Theall KP; Jiang Y; Bartlett CH; Koehler M; Slamon D
Lancet Oncol; 2016 Apr; 17(4):425-439. PubMed ID: 26947331
[TBL] [Abstract][Full Text] [Related]
8. Hematologic adverse events following palbociclib dose reduction in patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer: pooled analysis from randomized phase 2 and 3 studies.
Ettl J; Im SA; Ro J; Masuda N; Colleoni M; Schnell P; Bananis E; Lu DR; Cristofanilli M; Rugo HS; Finn RS
Breast Cancer Res; 2020 Mar; 22(1):27. PubMed ID: 32164785
[TBL] [Abstract][Full Text] [Related]
9. Endocrine treatment versus chemotherapy in postmenopausal women with hormone receptor-positive, HER2-negative, metastatic breast cancer: a systematic review and network meta-analysis.
Giuliano M; Schettini F; Rognoni C; Milani M; Jerusalem G; Bachelot T; De Laurentiis M; Thomas G; De Placido P; Arpino G; De Placido S; Cristofanilli M; Giordano A; Puglisi F; Pistilli B; Prat A; Del Mastro L; Venturini S; Generali D
Lancet Oncol; 2019 Oct; 20(10):1360-1369. PubMed ID: 31494037
[TBL] [Abstract][Full Text] [Related]
10. Real-World Treatment Patterns and Clinical Outcomes in Patients Receiving Palbociclib for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced or Metastatic Breast Cancer in Argentina: The IRIS Study.
Waller J; Mitra D; Mycock K; Taylor-Stokes G; Milligan G; Zhan L; Iyer S
J Glob Oncol; 2019 May; 5():JGO1800239. PubMed ID: 31050919
[TBL] [Abstract][Full Text] [Related]
11. Long-term Pooled Safety Analysis of Palbociclib in Combination With Endocrine Therapy for HR+/HER2- Advanced Breast Cancer.
Diéras V; Rugo HS; Schnell P; Gelmon K; Cristofanilli M; Loi S; Colleoni M; Lu DR; Mori A; Gauthier E; Huang Bartlett C; Slamon DJ; Turner NC; Finn RS
J Natl Cancer Inst; 2019 Apr; 111(4):419-430. PubMed ID: 30032196
[TBL] [Abstract][Full Text] [Related]
12. Palbociclib plus letrozole as first-line therapy in estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer with extended follow-up.
Rugo HS; Finn RS; Diéras V; Ettl J; Lipatov O; Joy AA; Harbeck N; Castrellon A; Iyer S; Lu DR; Mori A; Gauthier ER; Bartlett CH; Gelmon KA; Slamon DJ
Breast Cancer Res Treat; 2019 Apr; 174(3):719-729. PubMed ID: 30632023
[TBL] [Abstract][Full Text] [Related]
13. Palbociclib: A Novel Cyclin-Dependent Kinase Inhibitor for Hormone Receptor-Positive Advanced Breast Cancer.
Mangini NS; Wesolowski R; Ramaswamy B; Lustberg MB; Berger MJ
Ann Pharmacother; 2015 Nov; 49(11):1252-60. PubMed ID: 26324355
[TBL] [Abstract][Full Text] [Related]
14. Palbociclib Plus Letrozole as First-Line Therapy in Postmenopausal Asian Women With Metastatic Breast Cancer: Results From the Phase III, Randomized PALOMA-2 Study.
Im SA; Mukai H; Park IH; Masuda N; Shimizu C; Kim SB; Im YH; Ohtani S; Huang Bartlett C; Lu DR; Iyer S; Mori Y; Mori A; Gauthier E; Finn RS; Toi M
J Glob Oncol; 2019 May; 5():1-19. PubMed ID: 31125276
[TBL] [Abstract][Full Text] [Related]
15. Palbociclib in combination with fulvestrant in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: PALOMA-3 subgroup analysis of Japanese patients.
Masuda N; Inoue K; Nakamura R; Rai Y; Mukai H; Ohno S; Hara F; Mori Y; Hashigaki S; Muramatsu Y; Nagasawa T; Umeyama Y; Huang X; Iwata H
Int J Clin Oncol; 2019 Mar; 24(3):262-273. PubMed ID: 30392115
[TBL] [Abstract][Full Text] [Related]
16. Overall survival results from the randomized phase 2 study of palbociclib in combination with letrozole versus letrozole alone for first-line treatment of ER+/HER2- advanced breast cancer (PALOMA-1, TRIO-18).
Finn RS; Boer K; Bondarenko I; Patel R; Pinter T; Schmidt M; Shparyk YV; Thummala A; Voitko N; Bananis E; McRoy L; Wilner K; Huang X; Kim S; Slamon DJ; Ettl J
Breast Cancer Res Treat; 2020 Sep; 183(2):419-428. PubMed ID: 32683565
[TBL] [Abstract][Full Text] [Related]
17. Impact of palbociclib plus letrozole on patient-reported health-related quality of life: results from the PALOMA-2 trial.
Rugo HS; Diéras V; Gelmon KA; Finn RS; Slamon DJ; Martin M; Neven P; Shparyk Y; Mori A; Lu DR; Bhattacharyya H; Bartlett CHUANG; Iyer S; Johnston S; Ettl J; Harbeck N
Ann Oncol; 2018 Apr; 29(4):888-894. PubMed ID: 29360932
[TBL] [Abstract][Full Text] [Related]
18. Quality of life with palbociclib plus fulvestrant in previously treated hormone receptor-positive, HER2-negative metastatic breast cancer: patient-reported outcomes from the PALOMA-3 trial.
Harbeck N; Iyer S; Turner N; Cristofanilli M; Ro J; André F; Loi S; Verma S; Iwata H; Bhattacharyya H; Puyana Theall K; Bartlett CH; Loibl S
Ann Oncol; 2016 Jun; 27(6):1047-1054. PubMed ID: 27029704
[TBL] [Abstract][Full Text] [Related]
19. Prognostic Factors for Overall Survival in Patients with Hormone Receptor-Positive Advanced Breast Cancer: Analyses From PALOMA-3.
Rugo HS; Cristofanilli M; Loibl S; Harbeck N; DeMichele A; Iwata H; Park YH; Brufsky A; Theall KP; Huang X; McRoy L; Bananis E; Turner NC
Oncologist; 2021 Aug; 26(8):e1339-e1346. PubMed ID: 34037282
[TBL] [Abstract][Full Text] [Related]
20. Palbociclib in combination with letrozole in patients with estrogen receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: PALOMA-2 subgroup analysis of Japanese patients.
Mukai H; Shimizu C; Masuda N; Ohtani S; Ohno S; Takahashi M; Yamamoto Y; Nishimura R; Sato N; Ohsumi S; Iwata H; Mori Y; Hashigaki S; Muramatsu Y; Nagasawa T; Umeyama Y; Lu DR; Toi M
Int J Clin Oncol; 2019 Mar; 24(3):274-287. PubMed ID: 30515674
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
